Geneva Health Forum
7th Edition: Precision Global Health in the Digital Age
April 10-12, 2018
Geneva, Switzerland
The call for contributions closed on the 2nd of October 2017.
Challenges in a product development partnership: a malaria treatment case study
by Luiza L, Costa Chaves G, Marques Torres Barboza T, de Paula Barros Gonçalves L and Stobbaerts EG.
Ciência & Saúde Coletiva, October 2017
New York Times [18 July, 2017]
“Escaping big pharma’s pricing with patent-free drugs”
El Pais [15 July, 2017]
“Cinco recetas para la salud global” – “Five recipes for global health”
Takeda [1 June, 2017]
“グローバルヘルス技術振興基金第二期への資金拠出について” – “Financial contribution to the second phase of GHIT”
Reuters [21 April, 2017]
“Progress in fighting tropical diseases but funding and conflicts pose challenges”
Radio Okapi [20 April, 2017]
“RDC: des efforts sont nécessaires pour éliminer les maladies tropicales négligées” – “DRC: efforts needed to eliminate neglected tropical diseases”
Devex [20 April, 2017]
“Commitments made on neglected tropical diseases at WHO summit”
Le Temps [19 April, 2017]
“Des progrès dans la lutte contre les maladies tropicales négligées” – “Progress in addressing neglected tropical diseases”
Le Monde [19 April, 2017]
“Mobilisation contre les maladies tropicales négligées” – “Mobilization against neglected tropical diseases”
Devex [18 April, 2017]
“Strides in progress on neglected tropical diseases as global partners meet”
Financial Times [18 April, 2017]
“The long road to elimination of neglected tropical diseases”
Financial Times [18 April, 2017]
“More engagement on neglected tropical diseases needed from drugmakers”
Healio [12 April, 2017]
“GHIT Fund awards $23 million for malaria, NTDs research”
ReAct
Action on Antibiotic Resistance (ReAct) Africa Annual Conference 2017
September 18-19, 2017
Machakos, Kenya
DNDi Africa’s Director, Monique Wasunna, gave a presentation on DNDi‘s various programme models.
IUPAC World Chemistry Congress 2017
July 9-14, 2017
São Paulo, Brazil
Charles Mowbray, Head of Discovery, DNDi presented on drug discovery for neglected diseases.